Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

If Kevetrin is given the breakthrough designation, it's possible to gain FDA approval right after phase 2. Take PCYC's Ibrutinib for treating MCL as an example. The drug received the breakthrough designation in April 2013 and the FDA approved it in November based on phase 2 data of 111 patients. So I would not be surprised at all if K is approved by the FDA in 2015 or sooner, depends on how phase 2 goes.